A phase 1, dose escalation study of evorpacept (ALX148) in patients with advanced solid tumors and lymphoma
This phase 1 clinical study (AT148001) is an open-label, multi-center, multiple-dose, dose-escalation, safety, PK, and PD study of evorpacept (ALX148). The phase 1 protocol will have 2 parts: a single agent dose escalation phase (Part 1) and a combination therapy phase (Part 2). Part 2 will include an initial dose escalation portion followed by a dose expansion portion. Approximately 184 adult patients are expected to be enrolled in the study.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
174
University of Colorado Denver
Denver, Colorado, United States
Yale University
New Haven, Connecticut, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Dose-limiting toxicities (Number of participants with a DLT)
Number of participants with a DLT
Time frame: Up to 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Rituxan
Standard of care chemotherapy
Standard of care chemotherapy
Dana Farber Cancer Institute
Boston, Massachusetts, United States
START-Midwest
Grand Rapids, Michigan, United States
Seattle Cancer Care Alliance
Seattle, Washington, United States
Seoul National University Bundang Hospital
Seongnam, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital, Yonsei University
Seoul, South Korea